Axsome: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Nov. 2, 2026, Axsome (NASDAQ:AXSM) announced total revenue reached $260 million, representing 52% year-over-year growth. Long-term investors care because sales gains across multiple psychiatric treatments indicate the business is effectively expanding its commercial reach. Three takeaways from management's comments highlight what lies ahead for shareholders. Sales of Auvelity, the company's treatment for major depressive disorder and Alzheimer's disease agitation, hit $208 million in the quarter. That marks a 53% year-over-year increase, driven by increased adoption by primary care prescribers and new patient starts. Management expects this momentum across both indications to push peak annual sales to multi-billion-dollar levels, showing how deeply the drug is penetrating its target markets. The company operates 10 late-stage clinical programs in its research and development pipeline, targeting conditions such as narcolepsy, fibromyalgia, and smoking cessation. Clinical trial readouts scheduled through 2027 present multiple opportunities to expand existing labels and introduce new therapies, creating long-term value beyond current commercial sales. Continue reading